Cantor Fitzgerald, L. P. Halozyme Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $8.4 Billion
- Q3 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 12,200 shares of HALO stock, worth $854,366. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,200
Previous 12,200
-0.0%
Holding current value
$854,366
Previous $894,000
-0.0%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
665Shares Held
128MCall Options Held
599KPut Options Held
455K-
Black Rock Inc. New York, NY17.6MShares$1.23 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$814 Million0.01% of portfolio
-
State Street Corp Boston, MA5.02MShares$351 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.29MShares$230 Million0.16% of portfolio
-
Invesco Ltd. Atlanta, GA3.25MShares$227 Million0.04% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...